Welcome to our dedicated page for ANBIO BIOTECHNOLOGY SEC filings (Ticker: NNNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anbio Biotechnology (NNNN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Global Market. Anbio files with the U.S. Securities and Exchange Commission in connection with its initial public offering and ongoing reporting obligations related to its global in vitro diagnostics business.
Investors can review Anbio’s registration statement on Form F-1, which describes its offering of Class A ordinary shares, intended use of proceeds for expanding its sales and distribution network, research and development, and working capital and general corporate purposes. Subsequent current reports on Form 6-K supply updates on significant corporate events. For example, a Form 6-K details the termination of YCM CPA INC. as Anbio’s independent registered public accounting firm and the appointment of HTL International, LLC, along with disclosures that there were no disagreements or reportable events as defined under Regulation S-K.
Through this page, users can monitor Anbio’s periodic and current reports to understand how it presents its IVD platforms, global operations and risk factors in official filings. Stock Titan enhances these documents with AI-powered summaries that explain key sections, helping readers interpret complex accounting, auditing and disclosure language. As new filings are posted to the SEC’s EDGAR system, they are made available here with structured access to exhibits and narrative sections.
In addition to registration and current reports, this page can be used to track future annual reports on Form 20-F, interim updates on Form 6-K and other relevant submissions, offering a centralized view of Anbio’s regulatory reporting history and governance developments.
Anbio Biotechnology filed Amendment No. 1 to its Form 20-F for the year ended December 31, 2025. The amendment’s sole purpose is to update the cover page to check that the company is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.
The company states that no other changes have been made to the original annual report and that the amendment does not reflect events after the original filing. As of December 31, 2025, there were 43,891,200 Class A Ordinary Shares and 100,000,000 Class B Ordinary Shares issued and outstanding.
Anbio Biotechnology CFO Song Suki has filed an initial insider ownership report on Form 3 for ticker NNNN. The filing establishes her status as an officer but does not report any insider buy, sell, or other share transactions in this submission.
Anbio Biotechnology director Hartzler Nancy filed a Form 3 insider report. The filing identifies her as a director of Anbio Biotechnology (ticker NNNN) and shows no reported transactions in company securities, with zero buys, zero sells, and no derivative exercises recorded.
Anbio Biotechnology CEO Michael Lau has filed an initial Form 3 as an officer of the company. This filing identifies him as the Chief Executive Officer but, in this excerpt, shows no reportable holdings or insider transactions in Anbio Biotechnology securities at the time of the filing.
Anbio Biotechnology executive Chris Tian, the company’s CBO, filed an initial Form 3 as a reporting person for NNNN. This filing does not list any transactions, holdings, or derivative positions, serving solely as a baseline disclosure of insider status at the company.
Anbio Biotechnology director XU CANY filed an initial ownership report on Form 3 as an insider of the company. The filing does not list any specific share holdings or recent transactions, serving only to formally register this individual’s insider status with the issuer.
Anbio Biotechnology, a Cayman Islands in vitro diagnostics company, files its annual report describing its global holding structure and recent listing on Nasdaq. The company completed an IPO of 1,600,000 Class A Ordinary Shares at $5.00 per share, raising gross proceeds of $8 million.
The capital structure is highly concentrated, with 43,891,200 Class A and 100,000,000 Class B shares outstanding; each Class B share carries 50 votes, giving two shareholders 99.22% of total voting power. Anbio highlights reliance on a small number of suppliers and customers, shifting revenue away from COVID-19 tests toward other IVD products, and significant regulatory, IVDR transition, data integrity and reimbursement risks.
The report also warns about potential volatility in its small public float, complexities of being a foreign private issuer and emerging growth company, and challenges in maintaining internal controls, cybersecurity, intellectual property protection, and experienced management capable of meeting U.S. public company requirements.
Anbio Biotechnology reported a change in its independent registered public accounting firm. On February 11, 2026, the Board of Directors and Audit Committee approved and ratified the appointment of GGF CPA LTD to audit the company’s financial statements, effective the same date. The report states that during the two most recent fiscal years ended December 31, 2025 and 2024, and subsequent interim periods before this engagement, neither the company nor anyone on its behalf consulted GGF CPA LTD. A letter from the former auditor, HTL International, LLC, addressed to the U.S. Securities and Exchange Commission is included as Exhibit 16.1.
Anbio Biotechnology has appointed Michael Zhang as a director, Chair of the Audit Committee, and member of the Nominating and Compensation Committees, effective January 21, 2026. He replaces Kenneth Li, whose departure was not due to any disagreement with the company’s operations, policies, or procedures.
Zhang has over 30 years of finance experience and has been a managing partner at Healthcare Alpha Management since 2014. The board determined he is independent under Nasdaq rules and qualifies as an “audit committee financial expert.” Under his offer letter, he will serve until a successor is elected and qualified and will receive US$30,000 per calendar year, payable on a semiannual basis.
Anbio Biotechnology changed its independent registered public accounting firm. The Board of Directors and Audit Committee approved and ratified the appointment of HTL International, LLC as the new auditor, effective November 10, 2025.
The report also references Exhibit 16.1, a letter from YCM CPA INC. addressed to the U.S. Securities and Exchange Commission. This update focuses on auditor succession and related administrative matters under a Form 6-K.